Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Evaluating the Use and Efficacy of Avonex and Plegridy in Pediatric Patients
Multiple Sclerosis
P11 - Poster Session 11 (5:30 PM-6:30 PM)
6-005

IM interferon beta-1a (Avonex®) and peginterferon beta-1a (Plegridy®) have been shown to be effective in placebo-controlled randomized trials and real-world evidence for adults with relapsing forms of multiple sclerosis (MS). However, there are limited data in pediatric patients with MS that are receiving these therapies.

Summarize the demographic/clinical characteristics and efficacy outcomes of individuals with pediatric-onset multiple sclerosis (POMS) who were treated with Avonex or Plegridy

Data from patients treated at the United States Network of Pediatric MS Centers (NPMSC) are entered into the Pediatric MS and Demyelinating Diseases (PeMSDD) database. The population studied includes individuals who have used IM interferon beta-1a (Avonex®) or SC peginterferon beta-1a (Plegridy®) for any length of time prior to age 18 and excludes those with primary progressive diagnosis as last MS diagnosis. Outcomes assessed when use became sustained (three months) include annualized relapse rate (ARR), time to first relapse, and time to MRI activity.

Overall, the NPMSC registry included 254 patients who have been treated by Avonex (n = 220), Plegridy (n= 32) or both treatments (n = 2) before the age of 18. An estimated 66.3% of patients on sustained Avonex and 72.9% of patients on sustained Plegridy were relapse-free the first year. ARR was 0.45 on Avonex and 0.33 for Plegridy. For Avonex-treated patients, 67.9% and 82.8% had no new T2 lesions or gadolinium lesions at 1 year, respectively. For Plegridy-treated patients, 52.5% and 77.9% had no new T2/gadolinium lesions at 1 year, respectively. An estimated 76.8% and 67.9% of patients would not have EDSS progression within 1 year while on Avonex and Plegridy, respectively.

The data from this registry are consistent with previously reported clinical and MRI effects of approved interferon beta therapies more traditionally utilized in adult populations.

 

Biogen provided funding for this study.

Authors/Disclosures
Melissa A. Wright, MD (University of Utah)
PRESENTER
Dr. Wright has nothing to disclose.
Bradley Barney (University of Utah) No disclosure on file
Skyler Peterson (University of Utah) No disclosure on file
Michael Waltz No disclosure on file
John W. Rose, MD, FAAN (Imaging and Neurosciences Center) The institution of Dr. Rose has received research support from National Multiple Sclerosis Society. The institution of Dr. Rose has received research support from Guthy Jackson Charitable Foundation. The institution of Dr. Rose has received research support from NIH . The institution of Dr. Rose has received research support from VA. The institution of Dr. Rose has received research support from Biogen. The institution of Dr. Rose has received research support from Friends of MS. Dr. Rose has received intellectual property interests from a discovery or technology relating to health care.
Mary R. Rensel, MD, FAAN (Cleveland Clinic) Dr. Rensel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Rensel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cycle Pharma. Dr. Rensel has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for biogen. Dr. Rensel has stock in Brain Fresh LLC . The institution of Dr. Rensel has received research support from NMSS. The institution of Dr. Rensel has received research support from Roche- Genentech .
Aaron W. Abrams, MD (Cleveland Clinic Foundation) Dr. Abrams has nothing to disclose.
Emmanuelle Waubant, MD, PhD, FAAN (USCF MS Center) Dr. Waubant has received personal compensation in the range of $500-$4,999 for serving as a Consultant for emerald pharmaceuticals. Dr. Waubant has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for elsevier. The institution of Dr. Waubant has received research support from NIH. The institution of Dr. Waubant has received research support from NMSS. The institution of Dr. Waubant has received research support from PCORI. The institution of Dr. Waubant has received research support from Race to Erase MS. The institution of Dr. Waubant has received research support from Roche. The institution of Dr. Waubant has received research support from Biogen. The institution of Dr. Waubant has received research support from Department of Defense. Dr. Waubant has received publishing royalties from a publication relating to health care.
Yolanda Wheeler No disclosure on file
Moses Rodriguez, MD, FAAN (Mayo Clinic Department Of Neurology) Dr. Rodriguez has received intellectual property interests from a discovery or technology relating to health care.
Jan-Mendelt Tillema, MD (Mayo Clinic) Dr. Tillema has nothing to disclose.
Lauren B. Krupp, MD, FAAN (NYU Langone Medical Center) Dr. Krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gerson Lerhman. Dr. Krupp has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for medscape. Dr. Krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NeuroLive. Dr. Krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Krupp has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Krupp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Krupp has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Cleveland Clinic. Dr. Krupp has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for MCIC. The institution of Dr. Krupp has received research support from Biogen. The institution of Dr. Krupp has received research support from National Multiple Sclerosis Society. Dr. Krupp has received intellectual property interests from a discovery or technology relating to health care.
Mark Gorman, MD The institution of Dr. Gorman has received research support from Pfizer. The institution of Dr. Gorman has received research support from Roche / Genetech .
Leslie A. Benson, MD (Children's Hospital Boston) The institution of Dr. Benson has received research support from ROHHAD Fight, Inc. The institution of Dr. Benson has received research support from Shore Foundation. The institution of Dr. Benson has received research support from Alexion Pharmacuticals. The institution of Dr. Benson has received research support from Biogen, Inc. The institution of Dr. Benson has received research support from NIH. Dr. Benson has received personal compensation in the range of $0-$499 for serving as a consultant with MA Department of public health. Dr. Benson has received personal compensation in the range of $5,000-$9,999 for serving as a consultant with National vaccine injury compensation program.
Timothy E. Lotze, MD, FAAN (Texas Children's Hospital) Dr. Lotze has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Department of Justice VICP. The institution of Dr. Lotze has received research support from NIH. The institution of Dr. Lotze has received research support from National MS Society. The institution of Dr. Lotze has received research support from Sarepta Therapeutics. The institution of Dr. Lotze has received research support from PTC THERAPEUTICS. The institution of Dr. Lotze has received research support from Avexis. Dr. Lotze has received publishing royalties from a publication relating to health care.
Nikita Shukla, MD (BCM) The institution of Dr. Shukla has received research support from Roche.
Soe S. Mar, MD, FAAN (Washington University School of Medicine) The institution of Dr. Mar has received research support from NIH.
Tanuja Chitnis, MD, FAAN (Brigham and Women's Hospital) Dr. Chitnis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Chitnis has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche-Genentech. Dr. Chitnis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Siemens. Dr. Chitnis has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Academic CME. The institution of Dr. Chitnis has received research support from Novartis. The institution of Dr. Chitnis has received research support from Sanofi. The institution of Dr. Chitnis has received research support from Octave. The institution of Dr. Chitnis has received research support from Genentech-Roche.
Teri Schreiner, MD, MPH, FAAN (University of Colorado/ Children's Hospital of Colorado) The institution of Dr. Schreiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CDC. Dr. Schreiner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. The institution of Dr. Schreiner has received research support from Roche Genentech.
Megan Vignos, PhD (Biogen) Dr. Vignos has stock in Biogen. Dr. Vignos has received personal compensation in the range of $100,000-$499,999 for serving as a Employee with Biogen.
Jonathan Planton, PharmD, BCGP (Biogen) Dr. Planton has nothing to disclose.
Theron C. Casper, PhD (University of Utah) The institution of Dr. Casper has received research support from NIH. The institution of Dr. Casper has received research support from The National Multiple Sclerosis Society. The institution of Dr. Casper has received research support from Roche. The institution of Dr. Casper has received research support from Biogen.